Indaptus Therapeutics is trading 14.71% higher at $2.54, with the reason for the October 15 move unclear.
- No fresh company announcement explaining the move surfaced in the search.
- The reported $24 million private-placement deadline extension to October 16 was announced earlier and does not establish a new catalyst today.
- The broader market was mixed, with the Nasdaq lower; available evidence does not show market sentiment explains the gain.